Association of chitotriosidase genotype with the development of non-alcoholic fatty liver disease

Hepatology Research

Volumn 43, Issue 3, 2013, Pages 267-275

  Di Rosa, Michelino ^a   Mangano, Katia ^a   De Gregorio, Corinne ^a   Nicoletti, Ferdinando ^a   Malaguarnera, Lucia ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Chitotriosidase; Genotype; Non alcoholic steatohepatitis; Predictor of fibrosis

Indexed keywords

CHITOTRIOSIDASE; FERRITIN;

ADULT; AGED; ALLELE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; FERRITIN BLOOD LEVEL; GENE DUPLICATION; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LIVER PROTECTION; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

EID: 84871975030     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2012.01063.x     Document Type: Article

References (34)

1. Amarapurkar D, Kamani P, Patel N etal. Prevalence of non-alcoholic fatty liver disease: population based study. Ann Hepatol 2007; 6: 161-3.
2. Adams LA, Lymp JF, St Sauver J etal. The natural history of nonalcoholic fatty liver disease: apopulation-based cohort study. Gastroenterology 2005; 129: 113-21.
3. Smith BW, Adams LA. Non-alcoholic fatty liver disease. Crit Rev Clin Lab Sci 2011; 48: 97-113.
4. Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L. Molecular mechanisms involved in NAFLD progression. J Mol Med 2009; 87: 679-95.
5. Bugianesi E, Leone N, Vanni E etal. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-40.
6. Targher G, Bertolini L, Poli F etal. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005; 54: 3541-6.
7. Villanova N, Moscatiello S, Ramilli S etal. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005; 42: 473-80.
8. Di Rosa M, Malaguarnera L. Genetic variants in candidate genes influencing NAFLD progression. J Mol Med (Berl) 2012; 90: 105-18.
9. Fusetti F, von Moeller H, Houston D etal. Structure of human chitotriosidase. Implications for specific inhibitor design and function of mammalian chitinaselike lectins. J Biol Chem 2002; 277: 25537-44.
10. Boot RG, Renkema GH, Strijland A, van Zonneveld AJ, Aerts JM. Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages. J Biol Chem 1995; 270: 26252-6.
11. Guo Y, He W, Boer AM etal. Elevated plasma chitotriosidase activity in various lysosomal storage disorders. J Inherit Metab Dis 1995; 18: 717-22.
12. Di Rosa M, Musumeci M, Scuto A, Musumeci S, Malaguarnera L. Effect of interferon-gamma, interleukin 10, lipopolysaccharide and tumor necrosis factor-alpha on chitotriosidase synthesis in human macrophages. Clin Chem Lab Med 2005; 43: 499-502.
13. Malaguarnera L, Musumeci M, Licata F, Di Rosa M, Messina A, Musumeci S. Prolactin induces chitotriosidase gene expression in human monocyte-derived macrophages. Immunol Lett 2004; 94: 57-63.
14. Malaguarnera L, Musumeci M, Di Rosa M, Scuto A, Musumeci S. Interferon-gamma, tumor necrosis factor- alpha, and lipopolysaccharide promote chitotriosidase gene expression in human macrophages. J Clin Lab Anal 2005; 19: 128-32.
15. Di Rosa M, Zambito AM, Marsullo AR, Volti GL, Malaguarnera L. Prolactin induces chitotriosidase expression in human macrophages through PTK, PI3-K, and MAPK pathways. J Cell Biochem 2009; 107: 881-9.
16. Canudas J, Cenarro A, Civeira F etal. Chitotriosidase genotype and serum activity in subjects with combined hyperlipidemia: effect of the lipid-lowering agents, atorvastatin and bezafibrate. Metabolism 2001; 50: 447-50.
17. Artieda M, Cenarro A, Gañán A etal. Serum chitotriosidase activity is increased in subjects with atherosclerosis disease. Arterioscler Thromb Vasc Biol 2003; 23: 1645-52.
18. Artieda M, Cenarro A, Gañán A etal. Serum chitotriosidase activity, a marker of activated macrophages, predicts new cardiovascular events independently of C-reactive protein. Cardiology 2007; 108: 297-306.
19. Karadag B, Kucur M, Isman FK, Hacibekiroglu M, Vural VA. Serum chitotriosidase activity in patients with coronary artery disease. Circ J 2008; 72: 71-5.
20. Di Rosa M, Dell'Ombra N, Zambito AM, Malaguarnera M, Nicoletti F, Malaguarnera L. Chitotriosidase and inflammatory mediator levels in Alzheimer's disease and cerebrovascular dementia. Eur J Neurosci 2006; 23: 2648-56.
21. Malaguarnera L, Di Rosa M, Zambito AM, Dell'Ombra N, Nicoletti F, Malaguarnera M. Chitotriosidase gene expression in Kupffer cells of non-alcoholic fatty liver disease patients. Gut 2006; 55: 1313-20.
22. Malaguarnera L, Di Rosa M, Zambito AM, Dell'Ombra N, Di Marco R, Malaguarnera M. Potential role of chitotriosidase gene in nonalcoholic fatty liver disease evolution. Am J Gastroenterol 2006; 101: 2060-9.
23. Malaguarnera L. Chitotriosidase: the yin and yang. Cell Mol Life Sci 2006; 63: 3018-29.
24. Boot RG, Renkema GH, Verhoek M, van Zonneveld AJ, Aerts JM. The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem 1998; 273: 25680-5.
25. Malaguarnera L, Simporè J, Prodi DA etal. A 24-bp duplication in exon 10 of human chitotriosidase gene from the sub-Saharan to the Mediterranean area: role of parasitic diseases and environmental conditions. Genes Immun 2003; 4: 570-4.
26. Malaguarnera L, Ohazuruike LN, Tsianaka C, Antic T, Di Rosa M, Malaguarnera M. Human chitotriosidase polymorphism is associated with human longevity in Mediterranean nonagenarians and centenarians. J Hum Genet 2010; 55: 8-12.
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-19.
28. Brunt EM, Kleiner DE, Behling C etal. Misuse of scoring systems. Hepatology 2011; 54: 369-70.
29. Nielsen DM, Ehm MG, Weir BS. Detecting marker-disease association by testing for Hardy-Weinberg disequilibrium at a marker locus. Am J Hum Genet 1998; 63: 1531-40.
30. Day CP, James OF. Steatohepatitis: a tale of two "hits. Gastroenterology 1998; 114: 842-5.
31. George DK, Goldwurm S, MacDonald GA etal. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 115: 1307-9.
32. Kadiiska MB, Burkitt MJ, Xiang QH, Mason RP. Iron supplementation generates hydroxyl radical in vivo. An ESR spin-trapping investigation. J Clin Invest 1995; 96: 1653-7.
33. Pietrangelo A. Iron, oxidative stress and liver fibrogenesis. J Hepatol 1998; 28 (Suppl 1): 8-13.
34. Kaneda H, Hashimoto E, Yatsuji S, Tokushige K, Shiratori K. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2006; 21: 1459-65.